Mergers & AcquisitionsBy The Online Investor Staff, updated Sun., Jun. 20, 1:44 AM
|This Slide: #2 of 100|
Slide #2. NeoGenomics, Inc. — Inivata Ltd
NeoGenomics, Inc. (NASDAQ:NEO)
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today that it has completed its acquisition of Inivata Ltd, a global, commercial stage liquid biopsy platform company headquartered in Cambridge, England.
NeoGenomics operate a network of cancer-focused testing laboratories in the United States as well as laboratories in Switzerland and Singapore. Co.'s testing services include the following: Cytogenetics (karyotype analysis), a study of chromosomes and their relationship to disease; Fluorescence In-Situ Hybridization, a molecular cytogenetic technique that focuses on detecting and localizing the presence or absence of specific DNA sequences and genes on chromosomes; Flow cytometry, a technique utilized to measure the characteristics of cell populations; Immunohistochemistry and Digital Imaging; Molecular testing; and Morphologic analysis, a process of analyzing cells under the microscope.
NEO SEC Filing Email Alerts Service
Open the NEO Page at The Online Investor »
Strong Buy (3.68 out of 4)